{"url_path":"/sec/alxo/8-k/2026-06-30/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/1810182/0001193125-26-290447-index.html","accession_number":"0001193125-26-290447","cik":"0001810182","ticker":"ALXO","issuer_name":"ALX ONCOLOGY HOLDINGS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1810182/0001193125-26-290447-index.html","primary_entity_key":"0001810182","primary_entity_name":"ALX ONCOLOGY HOLDINGS INC"},"word_count":89,"has_tables":true,"body_markdown":"Item 8.01 Other Events.\n\nIn connection with Dr. Goodman’s resignation, the Board appointed Scott Garland, an independent director of the Company, to serve as Chairman of the Board, effective as of June 29, 2026.\n\nIn connection with the Board changes referenced above, the Board approved the following composition of committees of the Board:\n\nAudit Committee\n\nRekha Hemrajani, Chair; Daniel J. Curran, M.D.; and Scott Garland.\n\n \n\nCompensation Committee\n\nChris Takimoto, M.D., Ph.D., F.A.C.P., Chair; and Scott Garland.\n\n \n\nCorporate Governance and Nominating Committee\n\nDaniel J. Curran, M.D., Chair; and Rekha Hemrajani."}